High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$4K
$4,432
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
ANTX
S
AN2 Therapeutics, Inc.
Williams Sarah Joanne
• Officer • Principal Accounting Officer
Sell to Cover
2026-03-03
$347
|
||||||
| ANTX |
AN2 Therapeutics, Inc.
|
Officer • Principal Accounting Officer
Sell to Cover
|
2026-03-03 | $347 | S | Form 4 |
|
ANTX
S
AN2 Therapeutics, Inc.
Eizen Joshua M
• Officer • See Remarks
Sell to Cover
2025-11-04
$3,214
|
||||||
| ANTX |
AN2 Therapeutics, Inc.
|
Officer • See Remarks
Sell to Cover
|
2025-11-04 | $3,214 | S | Form 4 |
|
ANTX
S
AN2 Therapeutics, Inc.
Prior Stephen David
• Officer • Chief Strategy Officer
Sell to Cover
2025-11-04
$872
|
||||||
| ANTX |
AN2 Therapeutics, Inc.
|
Officer • Chief Strategy Officer
Sell to Cover
|
2025-11-04 | $872 | S | Form 4 |